Literature DB >> 16168486

Lymphocytic infiltration and enlargement of the lacrimal glands: a new subtype of primary Sjögren's syndrome?

Ben Parkin1, Jason B Chew, Valerie A White, Graciela Garcia-Briones, Mukesh Chhanabhai, Jack Rootman.   

Abstract

PURPOSE: To review the clinical, radiologic, serologic, histopathologic, immunohistochemical, and molecular genetic features of patients having Sjögren's syndrome (SS) with lacrimal gland enlargement.
DESIGN: Retrospective case series review. PARTICIPANTS: Fourteen patients histopathologically diagnosed with SS with lacrimal enlargement. Twenty-three age- and gender-matched controls were used for comparison on radiologic analysis.
METHODS: Clinical and serologic data were determined directly or by chart review. Computed tomography images from patients were compared with those from the control group. Histopathologic sections were reviewed and graded using the Chisholm-Mason scale, and quantitative immunohistochemical analysis was applied. MAIN OUTCOME MEASURES: Clinically, patients were assessed for age, gender, onset, symptoms and signs, systemic features, treatment, and outcome. Existing histologic specimens were reviewed according to the Chisholm-Mason scale, and then the percentages of plasma cells containing immunoglobulin (Ig) A, IgG, and IgM were determined. Imaging was assessed for lacrimal gland thickness, prolapse, density, and margin contour; extraocular muscle size; orbital tissue displacement; and proptosis.
RESULTS: Clinical and histopathological data fulfilled the revised American-European criteria for primary SS in 79% of patients. Compared with other large series of primary SS patients, similarities were found with age, xerophthalmia, parotidomegaly, and articular involvement. Differences included a lower incidence of autoantibodies, xerostomia, and extraglandular features and a higher male-to-female ratio. In almost all patients (93%), the percentage of plasma cells positive for IgA was less than 70%, consistent with SS. Compared with controls, the lacrimal glands were enlarged significantly (P<0.0001) and prolapsed (P<0.001). Involved glands had blurred margins (P<0.007), caused displacement of adjacent tissues (P = 0.03), and were associated with hyperdense fat (P = 0.007). Lymphocytic infiltration of orbital fat was present in all patients for whom fat biopsy results were available. Three patients had monoclonal infiltrates, and 1 patient experienced subsequent extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue type, 4 years after presentation.
CONCLUSIONS: The criteria used to diagnose primary SS are controversial, but both diagnostic and quantitative immunohistochemical criteria suggest that these patients, with lacrimal gland enlargement resulting from lymphocytic infiltration, represent a new subtype of primary SS. This is clinically important in view of the increased risk of lymphoma associated with SS, compared with idiopathic nonspecific lacrimal inflammation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16168486     DOI: 10.1016/j.ophtha.2005.06.014

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  9 in total

1.  The value of 68 Ga-PSMA-11 positron emission tomography/computerized tomography in evaluating the lacrimal and salivary glands function.

Authors:  Jian-Fang Li; Lu-Ping Qin; Qing-Yu Wu; Xing-Hua Guo; Jie-Zheng Yang; Qi-Chang Wan; Mu-Hua Cheng; Liang-Jun Xie
Journal:  Clin Rheumatol       Date:  2022-01-28       Impact factor: 2.980

2.  Autoimmune dacryoadenitis of NOD/LtJ mice and its subsequent effects on tear protein composition.

Authors:  Máire E Doyle; Lori Boggs; Robert Attia; Lauren R Cooper; Daniel R Saban; Cuong Q Nguyen; Ammon B Peck
Journal:  Am J Pathol       Date:  2007-09-06       Impact factor: 4.307

Review 3.  [Typical questions from the rheumatologist to the ophthalmologist and cooperating radiologist].

Authors:  B Nölle; M Both; M Heller; J B Roider
Journal:  Z Rheumatol       Date:  2008-09       Impact factor: 1.372

4.  Lymphotoxin-beta receptor blockade reduces CXCL13 in lacrimal glands and improves corneal integrity in the NOD model of Sjögren's syndrome.

Authors:  Roy A Fava; Susan M Kennedy; Sheryl G Wood; Anne I Bolstad; Jadwiga Bienkowska; Adrian Papandile; John A Kelly; Clio P Mavragani; Margaret Gatumu; Kathrine Skarstein; Jeffrey L Browning
Journal:  Arthritis Res Ther       Date:  2011-11-01       Impact factor: 5.156

5.  Salivary Gland Scintigraphy in Patients with Sjogren's Syndrome: A local Experience with Dual-tracer.

Authors:  Wing Hang Luk; Jessie Tse Hang Yeung; Eliza Po Yan Fung; Chiu Ming Lok; Yuet Ming Ng
Journal:  Asia Ocean J Nucl Med Biol       Date:  2017

Review 6.  Optic neuritis as an initial presentation of primary Sjögren syndrome: A case report and literature review.

Authors:  Jia-Yue Sun; Zheng Liu; Peng Zhao; Tao Liu
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

7.  Dysregulated Marginal Zone B Cell Compartment in a Mouse Model of Sjögren's Syndrome with Ocular Inflammation.

Authors:  Niharika Singh; Ian Chin; Paul Gabriel; Emily Blaum; Sharmila Masli
Journal:  Int J Mol Sci       Date:  2018-10-11       Impact factor: 5.923

Review 8.  Innate Immunity and Biological Therapies for the Treatment of Sjögren's Syndrome.

Authors:  Amrita Srivastava; Helen P Makarenkova
Journal:  Int J Mol Sci       Date:  2020-12-01       Impact factor: 5.923

9.  Association of the Risk of Primary Sjögren's Syndrome With Fibrocystic Breast Disease: A Nationwide, Population-Based Study.

Authors:  Hsin-Hua Chen; Hsian-Min Chen; Ching-Heng Lin; Kuo-Tung Tang; Der-Yuan Chen; James Cheng-Chung Wei; Wen-Cheng Chao
Journal:  Front Med (Lausanne)       Date:  2021-07-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.